Drug Profile

CT 111

Alternative Names: CT-111

Latest Information Update: 06 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chantibody Therapeutics
Developer Chantibody Therapeutics; Shanghai Cell Therapy Group
Class Antineoplastics; Immunotherapies; Trispecific antibodies
Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; Vascular endothelial growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral)
25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com